Alflorex® is a food supplement for specific medical use in the treatment of people with irritable bowel syndrome. Typical symptoms include:

  • Flatulence
  • Diarrhoea
  • Stomach pain
  • Constipation
  • Abdominal bloating

Alflorex® contains the bacterial culture Bifidobacterium infantis 35624®, which is named specifically in the current S3 guideline1 of the German Gastroenterology Society (DGVS) and the German Society for Neurogastroenterology and Motility (DGNM)*.  It can provide relief from the typical symptoms of irritable bowel syndrome and restore balance to the intestinal flora.2

Bifidobacterium infantis 35624®

Alflorex® is the only product in Europe that contains the bacterial culture B. infantis 35624®, which has up to now only been available in the USA and Canada. B. infantis 35624® has undergone a thorough research programme over 15 years.

  • The efficacy and tolerability of B. infantis 35624® in patients with irritable bowel syndrome has been demonstrated in clinical trials.2
  • The German Gastroenterology Society mentions B. infantis 35624® specifically in its current S3 guideline1.*
  • The current guideline of the World Gastroenterology Organisation (WGO) explicitly mentions B. infantis 35624® under "Management of IBS" and confirms that B. infantis 35624® has the best evidence of efficacy in the treatment of irritable bowel syndrome of all the probiotics.3

Irritable bowel syndrome

Approximately 15% of the population report experiencing irritable bowel syndrome. Irritable bowel syndrome is more common in women (OR 1.46), particularly those under the age of 30 years. Irritable bowel syndrome as a condition has been been described throughout history - the Greek physician Hippocrates described patients with abdominal symptoms, abnormal stools, bloating and urgency to empty the bowels as much as 3,000 years ago - and the origin of the term is based on anecdotal symptom-based reports of patients with chronic recurrence of abdominal discomfort, associated with abnormal stools.

According to the S3 guideline2, irritable bowel syndrome (IBS) is defined as follows:

  • Chronic discomfort (e.g. abdominal pain, flatulence) persisting for more than 3 months2 for which both the patient and doctor believe there is a connection with the bowels, and generally associated with stool alterations (diarrhoea or constipation, or alternation between the two).
  • Symptoms should be bad enough to cause worry to the patient and/or to cause the patient to seek help, and they should be significant enough to cause relevant impairment of quality of life.
  • No other changes characteristic of other diseases commonly responsible for these symptoms must be present.

For more information, please visit the Alflorex website®.

* Evidence level B for IBS pain/bloating type

1 Layer P et. al.: S3-Leitlinie zur Definition, Pathophysiologie, Diagnostik und Therapie des Reizdarmsyndroms. Z Gastroenterol 2011; 49:237-293. (In Überarbeitung)

2 Whorwell PJ et al. Efficacy of an Encapsualted Probiotic Bifidobacterium infantis 35624 in Women with Irritable Bowel syndrome. Am J Gastroenertol 2006; 101(7): 1581-1590

3 World Gastroenterology Organisation Global Guidelines. Irritable Bowel Syndrome: a Global Perspective. 2015.